Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001104659-26-001305·AVENUE THERAPEUTICS, INC.
Schedule 13D ownership disclosure
AVENUE THERAPEUTICS, INC.
Common Stock, $0.0001 Par Value · CUSIP: 05360L403
Event date: 2026-01-02
- Filing-level shares
- 439,955.00
- Percent of class
- 13.4%
- Fortress Biotech, Inc.Reported CIK 0001429260
Shares: 439,955.00 · Class: 13.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-26-001305
- Form type
- SCHEDULE 13D/A
- Filer
- AVENUE THERAPEUTICS, INC.
- CIK
- CIK 1644963
- Filed
- Jan 06, 2026
- Reporting period
- Jan 02, 2026
- Description
- Schedule 13D beneficial ownership